Press Release Biotechnology 1 min read

Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development

Allink Biotherapeutics raised $47 million in Series A extension rounds led by Legend Capital and Meituan Long-Z Investment to advance its clinical-stage ADC and multi-specific antibody programs for oncology and immunology.

Lanchi Ventures Yuanbio Venture Capital 5Y Capital Lapam Capital Runzhang Venture Capital Allink Biotherapeutics Inc.
Press ReleaseDecember 16, 2025
Lanchi Ventures

Allink Biotherapeutics raised $47 million in Series A extension rounds led by Legend Capital and Meituan Long-Z Investment to advance its clinical-stage ADC and multi-specific antibody programs for oncology and immunology.

Related articles

Press ReleaseSeptember 16, 2026
ASSA ABLOY

ASSA ABLOY acquires PACLOCK in the US

September 16, 2026
Press ReleaseSeptember 16, 2026
MySize

MySize Announces $2.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

September 16, 2026
Press ReleaseSeptember 16, 2026
Xpansiv

Xpansiv to Acquire Formbay, Australia's AI-Enabled Renewable Energy Certificate and Compliance Technology Platform

September 16, 2026
← Back to all articles

Generated by Olivia 6